| Literature DB >> 36158262 |
Liu-Liu Cao1, Mei Peng1, Xiang Xie1, Gong-Quan Chen2, Shu-Yan Huang3, Jia-Yu Wang4, Fan Jiang5, Xin-Wu Cui4, Christoph F Dietrich6.
Abstract
Artificial intelligence (AI) is playing an increasingly important role in medicine, especially in the field of medical imaging. It can be used to diagnose diseases and predict certain statuses and possible events that may happen. Recently, more and more studies have confirmed the value of AI based on ultrasound in the evaluation of diffuse liver diseases and focal liver lesions. It can assess the severity of liver fibrosis and nonalcoholic fatty liver, differentially diagnose benign and malignant liver lesions, distinguish primary from secondary liver cancers, predict the curative effect of liver cancer treatment and recurrence after treatment, and predict microvascular invasion in hepatocellular carcinoma. The findings from these studies have great clinical application potential in the near future. The purpose of this review is to comprehensively introduce the current status and future perspectives of AI in liver ultrasound. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Deep learning; Diffuse liver diseases; Focal liver diseases; Machine learning; Radiomics; Ultrasound
Mesh:
Year: 2022 PMID: 36158262 PMCID: PMC9346461 DOI: 10.3748/wjg.v28.i27.3398
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.374
Figure 1Main structure of this review. AI: Artificial intelligence; FLLs: Focal liver lesions; HCC: Hepatocellular carcinoma.
Studies using artificial intelligence based on ultrasound for fatty liver disease diagnosis
|
|
|
|
|
|
|
| Fatty liver disease diagnosis | Liver biopsy | 55 patients with severe obesity, 38 of whom had fatty liver disease | Deep learning with B-mode image ultrasound | Sensitivity: 100%; specificity: 88%; accuracy: 96%; AUC: 0.98 | [ |
| Fatty liver disease diagnosis | Radiologist qualitative score | 157 ultrasound liver images from unknown number of participants | Deep learning with B-mode image ultrasound | Sensitivity: 95%; specificity: 85%; accuracy: 90.6%; AUC: 0.96 | [ |
| NAFLD assessment | MRI proton density fat fraction | 204 participants, 140 of whom had NAFLD, 64 control participants | One-dimensional CNNs | Sensitivity: 97%; specificity: 94%; accuracy: 96%; AUC: 0.98 | [ |
| NAFLD assessment | MRI proton density fat fraction | 135 adult participants with known or suspected NAFLD | Transfer learning with a pretrained CNN by four ultrasound views of liver routinely obtained | SCC: 0.81; AUC: 0.91 (PDFF ≥ 5%) | [ |
| NAFLD assessment | Liver biopsy | 295 subjects, 198 mild fatty liver, one moderate degree of fatty liver | DCNN-based organ segmentation with Gaussian mixture modeling for automated quantification of the HRI | ICC of two radiologists and DCNN were 0.919, 0.916, 0.734 | [ |
| The severity of fatty liver | Abdominal ultrasound | 21855 B-mode ultrasound images, 2070 patients with different severities from none to severe fatty liver | Pretrained CNN models with B-mode ultrasound images | The areas under the receiver operating characteristic curves were 0.974 (mild steatosis | [ |
AUC: Area under curve; CNN: Convolutional neural network; DCNN: Deep convolutional neural network; HRI: Hepato-renal index; ICC: Intraclass correlation; MRI: Magnetic resonance image; NAFLD: Nonalcoholic fatty liver disease; PDFF: Proton density fat fraction; SCC: Spearman correlation coefficient.
Figure 2Illustration of the flowchart of the application of deep learning and radiomics in focal liver lesions. These two methods were based on big data, which contained image preprocessing, feature extraction and model construction.
Studies using artificial intelligence based on ultrasound for focal liver lesion diagnosis
|
|
|
|
|
|
| Classifying different FLLs based on B-mode | ANN | Cyst: 29; hemangioma: 37; malignant tumor: 33 | Cyst | [ |
| Differentiating benign and malignant lesions based on B-mode | CNN | Benign lesions: 300; malignant lesions: 296 | All lesion accuracy: 84%; uncertain set of lesion accuracy: 79% | [ |
| Classifying different FLLs based on B-mode | ANN (sparse autoencoder) | Normal liver: 16; cyst: 44; hemangioma: 18; HCC: 30 | overall accuracy: 97.2%; overall sensitivity: 98%; overall specificity: 95.7% | [ |
| Differentiating benign and malignant lesions based on B-mode | FSVM | training set; DS1: benign lesions: 132, malignant lesions: 68; DS2: malignant liver cancer: 50, hepatocellular adenoma: 150, hemangioma: 35, focal nodular hyperplasia: 145, lipoma: 70 | DS1: accuracy: 97%, sensitivity: 100%, specificity: 95.5%, AUC: 0.984; DS2: accuracy: 95.1%, sensitivity: 92.0%, specificity: 95.5%, AUC: 0.971 | [ |
| Classifying different FLLs based on B-mode | CNN | Non-tumorous liver: 258, hemangioma: 17, HCC: 6, cyst: 30, focal nodular hyperplasia: 8 | AUC for tumor detection: 0.935; AUC for tumor discrimination (mean): 0.916 | [ |
| Diagnosing HCC based on B-mode | CNN | Malignant tumor: 1786; benign tumor: 427 | AUC for EV: 0.924 | [ |
| Differentiating benign and malignant lesions based on B-mode | CNN | HCC: 6; cyst: 6600; hemangioma: 5374; focal fatty sparing: 5110; focal fatty infiltration: 934 | IV: overall sensitivity: 83.9%; overall specificity: 97.1%; HCC detection rate: 85.3%; EV: overall sensitivity: 84.9%; overall specificity: 97.1%; HCC detection rate: 78.3% | [ |
| Classifying different FLLs based on CEUS | ANN | hemangioma: 16; focal fatty liver: 23; HCC: 41; metastatic tumor: 32 (hypervascular: 20 hypovascular: 12) | Accuracy: 94.5%; sensitivity: 93.2%; specificity: 89.7% | [ |
| Differentiating benign and malignant lesions based on CEUS | Deep belief networks | HCC: 6; hemangioma: 10; liver abscess: 4; metastases: 3; focal fatty sparing: 3 | Accuracy: 83.4%; sensitivity: 83.3%; specificity: 87.5% | [ |
| Differentiating benign and malignant lesions based on CEUS | SVM | Benign tumor: 30; malignant tumor: 22 | Accuracy: 90.3%; sensitivity: 93.1%; specificity: 86.9% | [ |
| Differentiating benign and malignant lesions based on CEUS | SVM | Benign tumor, HCC or metastatic tumor: 98 | Benign | [ |
| Differentiating benign and malignant lesions based on CEUS | Deep canonical correlation analysis + multiple kernel learning | Benign tumor: 46; malignant tumor: 47 | Accuracy: 90.4%; sensitivity: 93.6%; specificity: 86.9% | [ |
| Differentiating benign and malignant lesions based on CEUS | 3D-CNN | HCC: 2110; focal nodular hyperplasia: 2310 | Accuracy: 93.1%; sensitivity: 94.5%; specificity: 93.6% | [ |
| Differentiating benign and malignant lesions based on CEUS | Deep neural network | Focal nodular hyperplasia: 16; HCC: 30; hemangioma: 23; hypervascular metastasis: 11; hypovascular metastasis: 11 | Top accuracy: 88% | [ |
| Differentiating benign and malignant lesions based on CEUS | CNN | Development set: malignant tumor: 281, benign tumor: 82; testing set: malignant tumor: 164, benign tumor: 47 | Accuracy: 91.0%; sensitivity: 92.7%; specificity: 85.1%; AUC: 0.934 | [ |
ANN: Artificial neural network; AUC: Area under curve; CEUS: Contrast-enhanced ultrasound; CNN: Convolutional neural network; DS1: Database 1; DS2: Database 2; EV: External validation; FLL: Focal liver lesion; FSVM: Fuzzy support vector machine; HCC: Hepatocellular carcinoma; IV: Internal validation; SVM: Support vector machine; 3D: Three-dimensional.